OSI PRESENTS DATA ON DIPEPTIDYL PEPTIDASE IV INHIBITOR

OSI Pharmaceuticals has announced that (OSI) Prosidion, its UK subsidiary, presented preclinical research data on its Dipeptidyl Peptidase IV (DPIV) inhibitor, PSN9301, during the European Association for the Study of Diabetes 41st Annual Meeting, held recently in Athens, Greece. PSN9301 is a novel oral DPIV inhibitor currently undergoing Phase II clinical trials where its efficacy and safety are being evaluated in Type 2 diabetic patients.

PSN9301's rapid onset and short duration of action facilitate an optimal meal-related dosing regimen, which may enhance the physiological gain from meal-related increases in incretin hormone levels and reduce unwanted effects on other DPIV substrates between meals. Incretin hormones are secreted by specific cells located in the small intestine in response to food intake and act to stimulate insulin release.